DiabetOmics
Modality Dx is an innovator in rapid test technologies for risk assessment and diagnosis in maternal health, diabetes, and autoimmune disease. They focus on developing molecular Signatures to support patient care, disease prediction, and early intervention. The company leverages advanced data science, molecular innovation, and patented science to redefine disease detection, understanding, and treatment, aiming to improve healthcare outcomes and support pharmaceutical development.
Industries
Nr. of Employees
small (1-50)
DiabetOmics
Beaverton, Oregon, United States, North America
Products
Point-of-care preeclampsia biomarker test (glycosylated fibronectin)
A rapid point-of-care assay measuring glycosylated fibronectin intended for assessment and short-term prediction of preeclampsia in pregnant patients.
Point-of-care C‑peptide test
Rapid point-of-care assay for quantitative estimation of C‑peptide to support diabetes care and classification.
Point-of-care autoantibody panel for diabetes-related autoantibodies
Rapid POC tests targeting diabetes-associated autoantibodies (including GAD, IA-2 and insulin autoantibodies) intended for detection of adaptive immune response markers.
Oral fluid SARS‑CoV‑2 antibody test (EUA-authorized use)
An oral fluid antibody assay authorized for emergency use to qualitatively detect total SARS‑CoV‑2 antibodies in gingival crevicular fluid for identifying adaptive immune response.
Point-of-care preeclampsia biomarker test (glycosylated fibronectin)
A rapid point-of-care assay measuring glycosylated fibronectin intended for assessment and short-term prediction of preeclampsia in pregnant patients.
Point-of-care C‑peptide test
Rapid point-of-care assay for quantitative estimation of C‑peptide to support diabetes care and classification.
Point-of-care autoantibody panel for diabetes-related autoantibodies
Rapid POC tests targeting diabetes-associated autoantibodies (including GAD, IA-2 and insulin autoantibodies) intended for detection of adaptive immune response markers.
Oral fluid SARS‑CoV‑2 antibody test (EUA-authorized use)
An oral fluid antibody assay authorized for emergency use to qualitatively detect total SARS‑CoV‑2 antibodies in gingival crevicular fluid for identifying adaptive immune response.
Services
Custom molecular signature development
Collaborative development of condition-specific biomarker signatures using proteomic data and AI to deliver a validated diagnostic panel within accelerated timelines.
Drug development and therapeutic efficacy support
Use of molecular signatures and biomarker assays to support patient stratification, endpoint measurement, and assessment of therapeutic response for pharmaceutical programs.
Oral fluid test development partnerships
Partnerships to develop non-invasive saliva-based tests for disease risk screening and antibody detection across multiple disease indications.
Custom molecular signature development
Collaborative development of condition-specific biomarker signatures using proteomic data and AI to deliver a validated diagnostic panel within accelerated timelines.
Drug development and therapeutic efficacy support
Use of molecular signatures and biomarker assays to support patient stratification, endpoint measurement, and assessment of therapeutic response for pharmaceutical programs.
Oral fluid test development partnerships
Partnerships to develop non-invasive saliva-based tests for disease risk screening and antibody detection across multiple disease indications.
Expertise Areas
- Biomarker discovery and signature development
- Point-of-care diagnostic development
- Oral fluid (saliva) diagnostics
- Proteomics and glycosylation analysis
Key Technologies
- Molecular signature biomarker panels
- Oral fluid (saliva) sampling
- Point-of-care quantitative immunoassays
- Proteomics